Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Development and Validation of a Multi-Mineral Fluoride Mouthrinse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00642252
Recruitment Status : Completed
First Posted : March 25, 2008
Last Update Posted : March 25, 2015
Sponsor:
Collaborator:
The University of Texas Health Science Center at San Antonio
Information provided by (Responsible Party):
Dr. Robert L. Karlinsey, Indiana Nanotech, LLC

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary goals of this project are to determine the anticaries benefits of a prototype multi-mineral mouthrinse containing 225 ppm fluoride and 30 ppm of a Ca through the remineralization of enamel white-spots (non-cavitated lesions). The selection of patients with pre-existing white-spot lesions will permit an opportunity to evaluate the efficacy of the multi-mineral mouthrinse in reminerzalizing and/or inhibiting progression of enamel white-spot lesions.

Condition or disease Intervention/treatment Phase
Dental Caries Drug: Fluoride Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Development and Validation of a Multi-Mineral Fluoride Mouthrinse
Study Start Date : January 2012
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Minerals

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: B
226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse
 Drug: Fluoride
Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
Other Name: New mouthrinse
Active Comparator: A
ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)
 Drug: Fluoride
Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
Other Name: ACT fluoride mouthrinse


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Remineralization of non-cavitated enamel lesions. [ Time Frame: baseline, 6, 12, 18, 24 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

To participate in this study, panelists will be required to meet the following criteria:

  1. Subjects must be 13 - 65 years of age;
  2. Subjects must read and sign the Informed Consent prior to initiation of study procedures. All subjects will receive a copy of the signed Informed Consent;
  3. Subjects must have a reasonable functional dentition, without a large number of missing teeth, and teeth #'s 22-27 present;
  4. Have normal salivary gland function (unstimulated whole salivary flow rate equal to or greater than 0.25 ml/min and paraffin stimulated whole salivary flow rate equal to or at least 1.0 ml/min);
  5. Subjects must be willing to participate in the study, be able to follow the study directions, be willing to return for all specified visits at their appointed time, and to use the product as per instructions;
  6. Subjects must be in good general health based on medical history and oral soft and hard tissue examination.

Exclusion Criteria:

Criteria that will not permit participation in this study will be as follows:

  1. Any subject who is pregnant or lactating - based on oral interview only - as pregnancy may interfere with the outcome of the study;
  2. Any subject who has a systemic health condition such as diabetes that could affect the outcome of the study at the discretion of the examiner;
  3. Any subject who has an oral condition, such as excessive, untreated dental caries, periodontal disease, chronic dental neglect, or any oral pathology including xerostomia determined by oral examination and subject history that in the opinion of the dental examiner could affect the outcome of the study;
  4. Any subject who has full dentures, or full orthodontic appliances. No use of nightguards will be permitted during the study period;
  5. Any subject who uses oral care products (other than those permitted) during the treatment or wash-out periods;
  6. Any subject with an immunological disorders such as HIV positive, AIDS, and systemic Lupus Erythematosis;
  7. Any subject concurrently participating in another clinical study;
  8. Any subject currently taking antibiotics or other medications, which in the opinion of the Investigator/Examiner might influence the study outcome;
  9. Any subject with a history of sensitivity to oral products or allergies to ingredients in the products;
  10. Any subject who fails to keep any of their scheduled appointments.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00642252


Locations
Layout table for location information
United States, Indiana
Crispus Attucks Medical Magnet High School
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana Nanotech, LLC
The University of Texas Health Science Center at San Antonio
Investigators
Layout table for investigator information
Study Director: George K Stookey, PhD Indiana Nanotech
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Dr. Robert L. Karlinsey, Managing Member, Indiana Nanotech, LLC
ClinicalTrials.gov Identifier: NCT00642252     History of Changes
Other Study ID Numbers: Nanotech Phase II April 2008
First Posted: March 25, 2008    Key Record Dates
Last Update Posted: March 25, 2015
Last Verified: March 2015
Keywords provided by Dr. Robert L. Karlinsey, Indiana Nanotech, LLC:
remineraliation
pre-existing white-spot (non-cavitated) enamel lesions
Additional relevant MeSH terms:
Layout table for MeSH terms
Dental Caries
Tooth Demineralization
Tooth Diseases
Stomatognathic Diseases
 Fluorides
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs